Natco Pharma Analyst Review May 2026

This Natco Pharma analyst review for May 2026 covers the key data investors need for NATCOPHARM at its current price of Rs 1,165.50. Natco Pharma (NSE: NATCOPHARM) is a specialty pharma company with a market capitalisation of approximately Rs 20,000 crore, known for oncology APIs and first-to-file US generic drugs. The analyst consensus target of Rs 1,400 implies meaningful upside, and this Natco Pharma analyst review examines technical levels, business performance, valuation, and key risks that will determine whether NATCOPHARM achieves that target through FY27.

Click Here – Get Free Investment Predictions

Natco Pharma Company Snapshot May 2026

Natco Pharma’s oncology expertise, first-to-file strategy for US drugs going off-patent, and strong branded domestic formulations in oncology and hepatitis C provide a focused, high-margin business model. The table below summarises the key data referenced in this Natco Pharma analyst review.

Parameter	Value
NSE Ticker	NATCOPHARM
Sector	Pharmaceuticals – Branded and Generic
CMP (May 2026)	Rs 1,165.50
52 Week High	Rs 1,226.80
52 Week Low	Rs 789.00
Market Cap	Rs 20,000 Crore
Trailing P/E	20x
Analyst Consensus Target	Rs 1,400
Bull Case Target	Rs 1,750
Bear Case Target	Rs 1,000

Analyst Insight in This Natco Pharma Analyst Review

Senior Research Analyst Ankit Jaiswal flags Natco Pharma as a stock to watch in May 2026. At Rs 1,165.50, Ankit Jaiswal identifies key support in the Rs 805 to Rs 1107 band and resistance near Rs 1235. He suggests watching Natco Pharma for a potential move toward Rs 1,400, subject to Pharmaceuticals – Branded and Generic sector momentum and Nifty 50 direction. Ankit Jaiswal’s view is one input in this Natco Pharma analyst review and does not constitute a trade recommendation.

Technical Analysis in This Natco Pharma Analyst Review

At Rs 1,165.50, NATCOPHARM is trading within its 52-week band of Rs 789.00 to Rs 1,226.80. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.

Near-term support is identified in the Rs 805 to Rs 1107 band while resistance is seen in the Rs 1235 to Rs 1283 zone. A sustained move above Rs 1235 could open the path toward the analyst consensus target of Rs 1,400.

Screen the best stocks on the Univest Screener.

Key Support and Resistance Levels

• Support Zone: Rs 805 to Rs 1107 – investors tracking this Natco Pharma analyst review should watch for stabilisation or a bounce in this range as a potential accumulation signal for NATCOPHARM.
• Resistance Zone: Rs 1235 to Rs 1283 – a sustained close above Rs 1235 would be a positive breakout signal worth flagging in this Natco Pharma analyst review.
• Medium-Term Target: The analyst consensus of Rs 1,400 represents the base-case upside scenario identified in this Natco Pharma analyst review.

Business Segment Analysis

Oncology APIs and Branded Formulations (India)

This is the primary revenue and margin driver for Natco Pharma, directly supporting the earnings trajectory toward the consensus target of Rs 1,400.

US Generics (First-to-File Oncology Strategy)

This segment adds scale and diversification to Natco Pharma’s business model and is a meaningful EPS contributor through FY27 and FY28.

Hepatitis C and Specialty Therapeutic Molecules

This represents the medium-term growth frontier for Natco Pharma and a key re-rating catalyst for the stock over the next 12 to 24 months.

Valuation in This Natco Pharma Analyst Review

At Rs 1,165.50, Natco Pharma trades at a trailing P/E of 20x. This Natco Pharma analyst review presents three valuation scenarios: a bull case of Rs 1,750 on strong earnings delivery and sector tailwinds, a base case of Rs 1,400 at analyst consensus, and a bear case of Rs 1,000 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this Natco Pharma analyst review.

Scenario	Target Price	Key Condition
Bull Case	Rs 1,750	Strong earnings delivery and sector re-rating
Base Case (Consensus)	Rs 1,400	Moderate growth, analyst consensus estimate
Bear Case	Rs 1,000	Earnings miss or macro headwinds

Trade Outlook for Natco Pharma

Based on the technical and fundamental analysis in this Natco Pharma analyst review, investors might watch NATCOPHARM near the support zone of Rs 805 to Rs 1107 for potential opportunities. A flag above Rs 1235 could suggest improving momentum toward Rs 1,400. This article uses watch-and-flag language only and does not constitute a trade recommendation.

Key Risks for Natco Pharma in FY27

A well-rounded Natco Pharma analyst review must assess downside risks. Key risks for Natco Pharma include a macro slowdown affecting Pharmaceuticals – Branded and Generic sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in NATCOPHARM.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: Natco Pharma Analyst Review Verdict for 2026

This Natco Pharma analyst review concludes that at Rs 1,165.50, NATCOPHARM offers a defined risk-reward with a consensus target of Rs 1,400. The 52-week range of Rs 789.00 to Rs 1,226.80 provides context on the current entry point. Use this Natco Pharma analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on NATCOPHARM.

Frequently Asked Questions: Natco Pharma Analyst Review 2026

What is the analyst target for Natco Pharma in 2026?

The analyst consensus target is Rs 1,400, with a bull case of Rs 1,750 and a bear case of Rs 1,000. Monitor Q1 FY27 earnings for confirmation as highlighted in this Natco Pharma analyst review.

Is Natco Pharma a good investment at Rs 1,165.50?

At Rs 1,165.50 with a P/E of 20x and a consensus target of Rs 1,400, this Natco Pharma analyst review is constructive for medium to long-term investors in the Pharmaceuticals – Branded and Generic sector. Always consult a SEBI-registered advisor before investing.

What is Natco Pharma’s 52-week high and low?

The 52-week high is Rs 1,226.80 and the 52-week low is Rs 789.00. At Rs 1,165.50, NATCOPHARM is positioned within this range as noted in this Natco Pharma analyst review.

What are the key risks for Natco Pharma?

Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals – Branded and Generic sector as assessed in this Natco Pharma analyst review.

Where can I track live data for Natco Pharma?

Track Natco Pharma’s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this Natco Pharma analyst review.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.